Immunoglobulins with reduced aggregation

Patent metadata

Field	Value
Publication number	US-9676841-B2
Application number	US-201414265149-A
Country	US
Kind code	B2
Filing date	Apr 29, 2014
Priority date	Jun 20, 2008
Publication date	Jun 13, 2017
Grant date	Jun 13, 2017

Abstract

The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease.

First claim

What we claim is:

1. A modified immunoglobulin formulation comprising a modified or isolated immunoglobulin having reduced propensity for aggregation comprising at least one aggregation reducing mutation at a residue in a conserved domain of the immunoglobulin that (i) has a Spatial-Aggregation-Propensity (5 Å radius sphere) of at least 0.15, or (ii) has an Spatial-Aggregation-Propensity (5 Å radius sphere) of greater than 0.0 and is within 5 Å of a residue having a Spatial-Aggregation-Propensity (5 Å radius sphere) of at least 0.15, wherein the at least one aggregation reducing mutation is a substitution with an amino acid residue that lowers the Spatial-Aggregation-Propensity (5 Å radius sphere) of the residue as compared to the unmutated immunoglobulin and the propensity for aggregation that is reduced is aggregation between immunoglobulin molecules in a concentrated, liquid solution, wherein the at least one aggregation reducing mutation is not at residue 234 (hinge) or 235 (hinge), wherein the modified or isolated immunoglobulin is at a concentration of at least 75 mg/ml, wherein at least eighty percent of the modified or isolated immunoglobulin is non-aggregated monomer, and wherein the modified or isolated immunoglobulin comprises a substitution at 282 (C H2 ).

2. The modified immunoglobulin formulation of claim 1 further comprising at least one additional aggregation reducing mutation residue selected from the group consisting of residues from an aggregation motif 1: 174 (C H1 ), 175 (C H1 ), and 181 (C H1 ); an aggregation motif 2: 226 (hinge), 227 (hinge), 228 (hinge), 229 (hinge), 230 (hinge), 231 (hinge), and 232 (hinge); an aggregation motif 3: 234 (hinge) and 235 (hinge); an aggregation motif 4: 252 (C H2 ), and 253 (C H2 ); an aggregation motif 6: 291 (C H2 ); an aggregation motif 7: 296 (C H2 ); an aggregation motif 8: 308 (C H2 ); an aggregation motif 9: 328 (C H2 ), 329 (C H2 ), 330 (C H2 ), and 331 (C H2 ); an aggregation motif 10: 395 (C H3 ), 396 (C H3 ), 397 (C H3 ), 398 (C H3 ), and 404 (C H3 ); an aggregation motif 11: 443 (C H3 ); an aggregation motif 12: 110 (C L ) and 111 (C L ); an aggregation motif 13: 153 (C L ) and 154 (C L ); and an aggregation motif 14: 201 (C L ).

3. The modified immunoglobulin formulation of claim 2 wherein the at least one aggregation reducing mutation residue is (i) selected from the group consisting of residues from an aggregation motif 1: 175 (C H1 ); an aggregation motif 2: 227 (hinge), 228 (hinge), and 230 (hinge); an aggregation motif 3: 234 (hinge) and 235 (hinge); an aggregation motif 4: 253 (C H2 ); an aggregation motif 6: 291 (C H2 ); an aggregation motif 7: 296 (C H2 ); an aggregation motif 9: 329 (C H2 ) and 330 (C H2 ); an aggregation motif 10: 395 (C H3 ) and 398 (C H3 ); an aggregation motif 11: 443 (C H3 ); an aggregation motif 12: 110 (C L ); an aggregation motif 13: 154 (C L ); and an aggregation motif 14: 201 (C L ).

4. A modified immunoglobulin formulation comprising a modified or isolated immunoglobulin having reduced propensity for aggregation comprising at least one aggregation reducing mutation, wherein the at least one aggregation reducing mutation is not at residue 234 (hinge) or 235 (hinge), and wherein the modified or isolated immunoglobulin comprises at least one aggregation reducing mutation at residue 282 (C H2 ), wherein residue 282 is mutated to a lysine, wherein the modified or isolated immunoglobulin is at a concentration of at least 75 mg/ml, and wherein at least eighty percent of the modified or isolated immunoglobulin is non-aggregated monomer.

5. The modified immunoglobulin formulation of claim 1 wherein the aggregation reducing mutation is a substitution with an amino acid residue that is less hydrophobic than the residue in the unmodified immunoglobulin.

6. The modified immunoglobulin formulation of claim 1 wherein the immunoglobulin further comprises a binding affinity for a target antigen and the binding affinity for the target antigen is at least seventy percent of the binding affinity of the unmutated immunoglobulin for the target antigen.

7. The modified immunoglobulin formulation of claim 1 wherein at least eighty-five percent of the modified or isolated immunoglobulin is non-aggregated monomer.

8. The modified immunoglobulin formulation of claim 1 further comprising a pharmaceutically acceptable excipient.

9. The modified immunoglobulin formulation of claim 1 wherein the immunoglobulin formulation shows at least five percent less aggregate after twenty four hours of accelerated aggregation as compared to the unmutated immunoglobulin under the same conditions.

10. The modified immunoglobulin formulation of claim 1 wherein the immunoglobulin formulation is substantially free of any additive that reduces aggregation of immunoglobulins.

11. An isolated or recombinant polynucleotide encoding the immunoglobulin of claim 1 .

12. A vector comprising the polynucleotide of claim 11 , optionally comprising an inducible promoter operably linked to the polynucleotide.

13. A host cell comprising the vector of claim 12 .

14. A method of producing an immunoglobulin with a reduced aggregation propensity comprising:
(a) providing a culture medium comprising the host cell of claim 13 ; and
(b) placing the culture medium in conditions under which the immunoglobulin is expressed; and
(c) optionally, isolating the immunoglobulin.

15. A modified immunoglobulin formulation comprising a modified or isolated immunoglobulin having reduced propensity for aggregation comprising at least one aggregation reducing mutation at a residue in a conserved domain of the immunoglobulin that (i) has a Spatial-Aggregation-Propensity (5 Å radius sphere) of at least 0.15, or (ii) has an Spatial-Aggregation-Propensity (5 Å radius sphere) of greater than 0.0 and is within 5 Å of a residue having a Spatial-Aggregation-Propensity (5 Å radius sphere) of at least 0.15, wherein the aggregation reducing mutation is a substitution with an amino acid residue that lowers the Spatial-Aggregation-Propensity (5 Å radius sphere) of the residue as compared to the unmutated immunoglobulin and the propensity for aggregation that is reduced is aggregation between immunoglobulin molecules in a concentrated, liquid solution, and a second aggregation reducing mutation at a residue that (i) has a Spatial-Aggregation-Propensity (5 Å radius sphere) of at least 0.15, or (ii) has an Spatial-Aggregation-Propensity (5 Å radius sphere) of greater than 0.0 and is within 5 Å of a residue having a Spatial-Aggregation-Propensity (5 Å radius sphere) of at least 0.15, wherein the second aggregation reducing mutation is a substitution with an amino acid residue that lowers the Spatial-Aggregation-Propensity (5 Å radius sphere) of the residue as compared to the unmutated immunoglobulin, wherein the aggregation reducing mutation and the second aggregation reducing mutation are in different aggregation motifs, wherein the modified or isolated immunoglobulin is at a concentration of at least 75 mg/ml, wherein at least eighty percent of the modified or isolated immunoglobulin is non-aggregated monomer, and wherein the modified or isolated immunoglobulin comprises a substitution at 282 (C H2 ).

16. The modified immunoglobulin formulation of claim 15 wherein the aggregation reducing mutation is a substitution with an amino acid residue that is less hydrophobic than the residue in the unmodified immunoglobulin.

17. The modified immunoglobulin formulation of claim 15 wherein the immunoglobulin further comprises a binding affinity for a target antigen and the binding affinity for

Assignees

• Novartis Ag
• Massachusetts Inst Technology

Inventors

• Chennamsetty Naresh
• Helk Bernhard
• Kayser Veysel
• Trout Bernhardt
• Voynov Vladimir

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title